Anifrolumab Shows Promise in SLE: Remission in 26% at 6 Months

A new analysis of real-world data offers encouraging insights into the effectiveness of anifrolumab, a medication recently approved for systemic lupus erythematosus (SLE). Published in The Lancet Rheumatology, the study reveals that approximately 26% of patients experienced clinical remission after six months of treatment, while a substantial 66% achieved a state of low disease activity. These findings, stemming from an ongoing, multi-center study in Italy, suggest anifrolumab could represent a valuable tool in managing this complex autoimmune condition, potentially offering benefits beyond those observed in controlled clinical trials.

Understanding Anifrolumab and SLE

Systemic lupus erythematosus is a chronic autoimmune disease that can affect many different body systems, including the joints, skin, kidneys, blood cells, brain, heart, and lungs. The disease is characterized by periods of flares (when symptoms worsen) and remissions (when symptoms improve). Treatment often involves a combination of medications aimed at suppressing the immune system and managing specific symptoms. The Mayo Clinic provides a comprehensive overview of SLE, its symptoms, and diagnostic approaches.

Anifrolumab, marketed as Safnelo by AstraZeneca, is a fully human monoclonal antibody that targets the type I interferon receptor. Type I interferons are proteins that play a role in the immune response, and they are often found to be elevated in people with SLE. By blocking the type I interferon receptor, anifrolumab aims to reduce inflammation and disease activity. The drug received FDA approval in 2023, but real-world data on its effectiveness and safety were limited until now.

REVEAL Study: A Real-World Look at Anifrolumab’s Impact

The data presented in The Lancet Rheumatology come from an interim analysis of the REVEAL study, a five-year prospective study tracking adults with active SLE receiving anifrolumab in routine clinical practice across Italy. Researchers analyzed data from 236 patients with a mean age of 46.9 years who had been living with the disease for an average of 11 years. The study focused on patients receiving anifrolumab for various SLE manifestations, with mucocutaneous (affecting the skin and mucous membranes) and articular (affecting the joints) involvement being the most common indications, reported in 67% and 49% of patients, respectively.

The primary outcome measured was the proportion of patients achieving clinical remission or a low disease activity state (LLDAS). LLDAS was defined as having minimal disease activity with a low dose of prednisone (a corticosteroid) – specifically, 7.5 mg or less per day. A more stringent measure, LLDAS5, required a prednisone equivalent dose of 5 mg or less per day. Researchers also tracked adverse events, including infections, to assess the safety profile of the drug.

Key Findings and What They Mean

The results showed a significant proportion of patients benefiting from anifrolumab treatment. At the six-month mark, 26% of patients had achieved clinical remission, meaning their disease activity was minimal or absent. 66% reached LLDAS, indicating a substantial reduction in disease activity, and 57% met the criteria for LLDAS5, demonstrating a particularly low level of disease activity with minimal corticosteroid use.

These findings are particularly noteworthy because they reflect outcomes in a “real-world” setting, where patients may have more diverse characteristics and co-existing conditions than those enrolled in highly controlled clinical trials. The study suggests that anifrolumab’s benefits extend beyond the specific populations studied in the initial clinical trials, potentially benefiting a broader range of SLE patients. Healio previously reported on the positive results of the TULIPSC trial, which supported the FDA approval of anifrolumab.

Safety Considerations

As with any immunosuppressant medication, safety is a crucial consideration. During the six-month period, researchers reported 108 complications among the study participants, with the majority (83) being infection-related. Five of these complications were classified as serious. Six patients required hospitalization during the study period. These findings underscore the importance of careful monitoring for infections and other potential adverse events in patients receiving anifrolumab.

Limitations and Future Directions

It’s critical to acknowledge the limitations of this study. As an interim analysis of an ongoing five-year study, the long-term effects of anifrolumab remain unknown. The study was conducted in a single country (Italy), which may limit the generalizability of the findings to other populations. The study design, while prospective, does not include a control group, making it hard to definitively attribute the observed improvements solely to anifrolumab. Other factors, such as concurrent medications or lifestyle changes, may have contributed to the observed outcomes.

The researchers emphasize that further investigation is needed to fully understand the long-term efficacy and safety of anifrolumab in diverse SLE populations. Ongoing analysis of the REVEAL study, as well as additional research, will be crucial to refine treatment strategies and optimize patient care. The study also highlights the need for continued surveillance of adverse events and the development of strategies to mitigate potential risks.

What’s Next for SLE Treatment?

The findings from the REVEAL study contribute to a growing body of evidence supporting the use of targeted therapies, like anifrolumab, in the management of SLE. These therapies offer the potential to address specific aspects of the disease process, potentially leading to more effective and personalized treatment approaches. Healio previously explored the promise of targeted therapies in achieving steroid- and immunosuppression-free remission in lupus.

Researchers are continuing to investigate new therapeutic targets and develop innovative treatments for SLE. Clinical trials are underway to evaluate the efficacy of other novel agents, and efforts are focused on identifying biomarkers that can predict treatment response and personalize therapy. The ultimate goal is to develop treatments that can effectively control SLE, prevent organ damage, and improve the quality of life for people living with this challenging condition. The National Institute of Allergy and Infectious Diseases (NIAID) provides information on ongoing research and clinical trials related to lupus: https://www.niaid.nih.gov/diseases-conditions/lupus.